In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher
titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the …

Antiphospholipid syndrome (APS) consists of thrombotic, non-thrombotic and obstetric
clinical manifestations developing in individuals with persistent antiphospholipid antibodies …

Neutrophil hyperactivity and neutrophil extracellular trap release (NETosis) appear to play
important roles in the pathogenesis of the thromboinflammatory autoimmune disease known …

Importance Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterized by inflammation and immune-mediated injury to multiple organ systems …

Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition
characterized by the persistence of antiphospholipid antibodies and occurrence of multiple …

Objectives This study aimed to assess the performance of cardiovascular risk (CVR)
prediction models reported by European Alliance of Associations for Rheumatology and …

Thrombotic antiphospholipid syndrome (TAPS) is characterized by thrombosis and
persistently positive tests for antiphospholipid antibodies or lupus anticoagulant (LAC) …

The latest consensus “guidelines” outlining revised Classification Criteria for
antiphospholipid syndrome (APS) has just been published. 1 The aim of this publication was …

Antibodies against phospholipid (aPL)-binding proteins, in particular, beta 2 glycoprotein I
(β2GPI), are diagnostic/classification and pathogenic antibodies in antiphospholipid …

APS patients exhibit a wide clinical heterogeneity in terms of the disease's origin and
progression. This diversity can be attributed to consistent aPL profiles and other genetic and …